Selected coverage of mantle cell lymphoma (MCL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California. Patients with TP53-mutant mantle ...
Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results